Clinical trials: Interstitial Disease
Idiopathic Pulmonary Fibrosis
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT07687459
- Testing
- INS018_055 tablets
- Where
- 47 sites in China
- Volunteers
- 320 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cystitis, Interstitial
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
- Trial name
- NCT00601484
- Testing
- PF-04383119
- Where
- 34 sites in United States
- Volunteers
- 65 people
- Sponsor
- Pfizer
Diabetes Mellitus
Performance Evaluation of a Novel Non-invasive Glucometer, Calibrated Against Validated Interstitial Glucose References
This clinical study has been launched to collect spectral Raman data on the Investigational Medical Device (IMD) compared with reference methods in terms of interstitial fluid samples and capillary and venous references.
- Trial name
- NCT03782649
- Testing
- Working Model 3.4NR
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- RSP Systems A/S
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Interstitial Cystitis
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
The purpose of this study is to assess the safety and tolerability of two doses of LP08 compared to placebo. Hypothesis: Safety of the LP-08 therapy will not be significantly different from the placebo group.
- Trial name
- NCT01393223
- Testing
- LP-08 80mg, Normal saline, LP-08 20mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Lipella Pharmaceuticals, Inc.
Idiopathic Pulmonary Fibrosis
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
This is a randomized, double-blind, placebo-controlled Phase 1 study of SAD (Part 1) and MAD (Part 2) of orally administered GNS-3545 in healthy adult subjects. The food effect will be assessed in one cohort in Part 1.
- Trial name
- NCT07225296
- Testing
- GNS-3545
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Genosco Inc.
Breast Neoplasms
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
The purpose of the study is to: compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the…
- Trial name
- NCT07096024
- Testing
- palbociclib plus fulvestrant, fulvestrant
- Where
- United States
- Volunteers
- 95,637 people
- Sponsor
- Pfizer
Lung Diseases, Interstitial
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).
- Trial name
- NCT06440746
- Testing
- Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
- Where
- 33 sites in Russia
- Volunteers
- 138 people
- Sponsor
- R-Pharm International, LLC
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period.
- Trial name
- NCT03261037
- Testing
- Spirometry, Accelerometry, 6MWT
- Where
- 37 sites in Canada, France and 4 more
- Volunteers
- 178 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess the efficacy and safety of the intravenous drip infusion of ART-123 in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) in a multicenter, double-blind, randomized…
- Trial name
- NCT02739165
- Testing
- ART-123
- Where
- 26 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Urinary Tract Infection Complicated, Acute Pyelonephritis
CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
The purpose of this study is to evaluate the effects of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) compared to Meropenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis…
- Trial name
- PLEA (NCT03477422)
- Testing
- CSE-1034 (Ceftriaxone + Sulbactam + EDTA), Meropenem
- Where
- 17 sites in India
- Volunteers
- 230 people
- Sponsor
- Venus Remedies Limited
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female…
- Trial name
- NCT03502902
- Testing
- HEC 68498
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe.
- Conditions
- Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
- Trial name
- NCT07201922
- Testing
- Nerandomilast
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers
Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue…
- Trial name
- NCT02690428
- Testing
- Immunostimulating Interstitial Laser Thermotherapy
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Clinical Laserthermia Systems AB
Wegener's Granulomatosis
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys.
- Trial name
- NCT00530075
- Testing
- Gusperimus
- Where
- 7 sites in Czechia, Denmark and 4 more
- Volunteers
- 45 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Lung Diseases, Interstitial
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).
- Trial name
- InPedILD® (NCT04093024)
- Testing
- Nintedanib
- Where
- 43 sites in United States, Argentina and 19 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
A Phase 2 open label, dose escalation study to find the minimally and maximum effective dose (dose beyond which no further effect on PVR is seen) of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.
- Trial name
- PHiano (NCT01265888)
- Testing
- Inhaled Nitric Oxide
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Geno LLC